325 related articles for article (PubMed ID: 32699984)
21. Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells.
Flis S; Bratek E; Chojnacki T; Piskorek M; Skorski T
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31614827
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
Ono T; Takahashi N; Kizaki M; Kawaguchi T; Suzuki R; Yamamoto K; Ohnishi K; Naoe T; Matsumura I
Cancer Sci; 2023 Mar; 114(3):995-1006. PubMed ID: 36336963
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
24. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
25. Bosutinib for the treatment of chronic myeloid leukemia.
Doan V; Wang A; Prescott H
Am J Health Syst Pharm; 2015 Mar; 72(6):439-47. PubMed ID: 25736937
[TBL] [Abstract][Full Text] [Related]
26. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
27. Bosutinib in chronic myeloid leukemia: patient selection and perspectives.
Isfort S; Brümmendorf TH
J Blood Med; 2018; 9():43-50. PubMed ID: 29695943
[TBL] [Abstract][Full Text] [Related]
28. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
Stansfield L; Hughes TE; Walsh-Chocolaad TL
Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
[TBL] [Abstract][Full Text] [Related]
29. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
30. Treatments for chronic myeloid leukemia: a qualitative systematic review.
Ferdinand R; Mitchell SA; Batson S; Tumur I
J Blood Med; 2012; 3():51-76. PubMed ID: 22915985
[TBL] [Abstract][Full Text] [Related]
31. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
32. BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Terasawa T; Dahabreh I; Trikalinos TA
PLoS Curr; 2010 Dec; 2():RRN1204. PubMed ID: 21188137
[TBL] [Abstract][Full Text] [Related]
33. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib.
Breccia M; Efficace F; Iurlo A; Luciano L; Abruzzese E; Gozzini A; Pregno P; Tiribelli M; Rosti G; Minotti G
Expert Opin Drug Saf; 2018 Jun; 17(6):623-628. PubMed ID: 29845876
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
35. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
36. Finding the right BCR-ABL1 tyrosine kinase inhibitor: a case report of successful treatment of a patient with chronic myeloid leukemia and a V299L mutation using nilotinib.
Elnair R; Galal A
BMC Cancer; 2018 Nov; 18(1):1097. PubMed ID: 30419862
[TBL] [Abstract][Full Text] [Related]
37. Second-generation TKIs: which and when?
Saglio G
Leuk Suppl; 2012 Aug; 1(Suppl 2):S40-2. PubMed ID: 27175246
[TBL] [Abstract][Full Text] [Related]
38. Selecting the best frontline treatment in chronic myeloid leukemia.
Yilmaz M; Abaza Y; Jabbour E
Curr Hematol Malig Rep; 2015 Jun; 10(2):145-57. PubMed ID: 25921387
[TBL] [Abstract][Full Text] [Related]
39. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
40. Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.
Shieh MP; Mitsuhashi M; Lilly M
Clin Med Insights Oncol; 2011; 5():185-99. PubMed ID: 21792346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
